Watch on YouTubeIndependent US payer research commissioned by Poolbeg Pharma shows strong commercial backing for POLB 001 — a first-in-class preventative for cancer immunotherapy-induced CRS. Chris from Acumentis Global on what payers said, and what it means for the commercial opportunity ahead.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Vox Markets Podcast
2413: Is EGT now set for revenues of £50m?
2412: RentGuarantor Revenues Surge 155%
2410: Great Southern Copper targets district-scale porphyry system in Chile
2409: Prospex Energy: The Bases Are Loaded as Asset Momentum Builds into 2027
Get summaries like this every morning.
Free AI-powered recaps of The Vox Markets Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.